Davila G Willy
Cleveland Clinic Foundation, Weston, FL 33331, USA.
Expert Opin Pharmacother. 2003 Dec;4(12):2315-24. doi: 10.1517/14656566.4.12.2315.
Overactive bladder has been successfully treated with oral anticholinergic drugs such as oxybutynin chloride. Although oral oxybutynin has been effective in controlling urinary urge incontinence and in decreasing incontinence episodes, adverse events, particularly dry mouth, often cause patients to discontinue oral therapy and to endure incontinence. Transdermal oxybutynin (Oxytrol, Watson Pharmaceuticals) is applied twice-weekly to maintain the efficacy of oral oxybutynin while significantly minimising side effects (e.g., dry mouth) that complicate therapy. By avoiding hepatic and gastrointestinal metabolism of oxybutynin, less N-desethyloxybutynin (N-DEO), the compound thought to be responsible for anticholinergic side effects, such as dry mouth, is produced. The new transdermal oxybutynin formulation offers patients with urinary incontinence an effective, safe and well-tolerated option for managing the symptoms of overactive bladder.
膀胱过度活动症已通过口服抗胆碱能药物如氯化奥昔布宁成功治疗。尽管口服奥昔布宁在控制尿急失禁和减少失禁发作方面有效，但不良事件，尤其是口干，常常导致患者停止口服治疗并忍受失禁。透皮奥昔布宁（Oxytrol，华生制药公司）每周应用两次，以维持口服奥昔布宁的疗效，同时显著减少使治疗复杂化的副作用（如口干）。通过避免奥昔布宁的肝脏和胃肠道代谢，产生的N-去乙基奥昔布宁（N-DEO）较少，该化合物被认为是导致抗胆碱能副作用如口干的原因。新的透皮奥昔布宁制剂为尿失禁患者提供了一种有效、安全且耐受性良好的选择，用于管理膀胱过度活动症的症状。
